Mictoryl® and Mictoryl® Pediatric now available and distributed in Canada by Duchesnay
Duchesnay Expands its Women’s Health Product Portfolio with Acquisition of Osphena® from Shionogi Inc.
Duchesnay Inc. is pleased to announce that Health Canada has granted market authorization for Mictoryl®/Mictoryl® Pediatric
Duchesnay Summarizes Comprehensive Body of Evidence for Most Studied Morning Sickness Drug Worldwide – Over 40 years of clinical experience, 16 cohort studies, two meta-analyses support regulatory approvals and guidelines –
Duchesnay donates $12,000 to Moisson Laurentides, surpassing our 2015 contribution of $10,000
2015-2016 Excellence Awards at the Université de Montréal Faculty of Pharmacy